Status:

COMPLETED

Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy Volunteers

Lead Sponsor:

Norgine

Conditions:

Fecal Incontinence

Eligibility:

All Genders

21-50 years

Phase:

PHASE1

Brief Summary

This study is conducted to explore the safety and tolerability and plasma pharmacokinetics of NRL001 after single intra-anal dose of 1mL cream at increasing concentrations.

Eligibility Criteria

Inclusion

  • IN.1) sex: male and female (non-child-bearing potential or using medically adequate contraception
  • IN.2) race: Caucasian
  • IN.3) BW: 50 - 100 kg
  • IN.4) BMI: 20 - 28 kg.m-2
  • IN.5) age: 21 - 50 years
  • IN.6) type: healthy on the basis of specified criteria evaluated at the screening visit
  • IN.7) willing and able to provide informed consent

Exclusion

  • General
  • EX.1) Previous participation in the trial
  • EX.2) Participant in any other trial during the last 90 days
  • EX.3) Donation of blood during the last 60 days or a history of blood loss exceeding 300 mL within the last 3 months
  • EX.4) History of any clinically relevant allergy (including hypersensitivity to the trial medications)
  • EX.5) Presence of acute or chronic infection
  • EX.6) Presence or history of any relevant co-morbidity
  • EX.7) Resting systolic blood pressure \> 140 or \< 90 mmHg, diastolic blood pressure \> 95 or \< 50 mmHg
  • EX.8) Clinically relevant ECG-abnormalities, prolonged QTc with \> 450 msec in males and \> 460 msec in females in particular
  • EX.9) Presence of any relevant abnormality in the laboratory safety tests, especially low haemoglobin, increased liver enzymes
  • EX.10) Positive serology for HBsAg, anti HBc and anti HCV
  • EX.11) Positive HIV test
  • EX.12) Positive alcohol or urine drug test on recruitment (and upon admission)
  • EX.13) History of alcohol and/or drug abuse and/or daily use of \> 30 gr alcohol
  • EX.14) Smoking more than 15 cigarettes/day or equivalent of other tobacco products
  • EX.15) Use of prohibited medication
  • EX.16) Suspicion or evidence that the subject is not trustworthy and reliable
  • EX.17) Suspicion or evidence that the subject is not able to make a free consent or to understand the information in this regard
  • General - all females
  • EX.18) Positive pregnancy test
  • EX.19) Lactating
  • EX.20) Not using appropriate contraception in pre-menopausal women (note: under the conditions of the present study, women using hormonal contraceptives will be informed that this method is not sufficient during the study and that further i.e. mechanical methods \[condom, diaphragm with spermicidal gel\] should be used in addition).

Key Trial Info

Start Date :

April 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2007

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT01406925

Start Date

April 1 2007

End Date

June 1 2007

Last Update

August 1 2011

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital MHAPT Zaritza Johanna

Sofia, Bulgaria

Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy Volunteers | DecenTrialz